Britannia Life Sciences Inc · CSE:BLAB
Britannia Life Sciences — Investor Presentation (January 2024)
20 slides from Britannia Life Sciences's investor presentation, January 2024
Slide 1: Tech-Enabled Laboratories
Tech-Enabled Laboratories – Jan 2024 – STRICTLY PRIVATE & CONFIDENTIAL
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain information set forth by Britannia Life Sciences (“BLS” or the “Company”) in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred
Slide 3: Company Summary
COMPANY SUMMARY • Britannia Life Sciences (CSE:BLAB) is a profitable public company focused on growing technology-enabled laboratories to drive higher margins and better customer results. • BLAB operates in the consumer goods and natural resources sectors, with facilities in the UK and US, and plans
Slide 4: Corporate Highlights
CORPORATE HIGHLIGHTS Britannia is focused on generating shareholder value through organic growth and acquisitions Calendar 2023 Milestones Shares Comment ✓ Acquired Paragon Geochemical via BMS Common Shares 162,254,339 Publicly traded ✓ Acquired control of Cosmetics Lab ✓ Goal to consolidate ownersh
Slide 5: Diverse Holdings
DIVERSE HOLDINGS Consumer Products Natural Resources (38% owned by BLAB) (Britannia Life Sciences) (Britannia Mining Solutions) 51% ownership 74% ownership 38% ownership 38% ownership NTM EBITDA $650k EBITDA $3.4mm EBITDA $2.0mm NTM EBITDA $1.8mm Technology Layer (BLABtech) Strategic tech consistent
Slide 6: Technology Layer
TECHNOLOGY LAYER Britannia’s sustainable competitive advantage is achieved by implementing technology in traditional lab settings Product & Consumer AI & Machine Learning PhotonAssay & Mining Tech Management Systems Leverage more robust data for Expands and optimizes product Disrupt status quo with
Slide 7: Illustrative AI Deals
ILLUSTRATIVE AI DEALS Britannia has identified and is currently undergoing due diligence to acquire distressed companies with AI-based platforms and significant potential. Lab-Grown Human Interface AI Consumer Trials Platform Decentralized Analytical and Stability Production of artificial human skin
Slide 8: EBITDA Margin Comparison by Segment
EBITDA MARGIN COMPARISON BY SEGMENT Britannia Life Sciences Competitors Cosmetics & CPG Fire Assay PhotonAssay Various Industries 55% margin 41% margin 50% margin 17-24% margin Britannia has proven its ability to grow market share and materially improve EBITDA, by focusing on traditionally low-tech
Slide 9: Consumer Packaged Goods
CONSUMER PACKAGED GOODS Te s t i n g o f C o s m e t i c s , F o o d , N u t r a c e u t i c a l s
Slide 10: Consumer Products Platform
CONSUMER PRODUCTS PLATFORM • Product development, analytical testing and compliance platform that now includes manufacturing for high-end cosmetics • Platform provides end-to-end solutions for companies from startups to multinationals globally • UK-based cosmetics manufacturing allows brands to scal
Slide 11: Growth Opportunities in CPG
GROWTH OPPORTUNITIES IN CPG • Over its history, Britannia has established a reputation of customer Retail service excellence, leading to strong customer retention • Repeat customers account for almost 90% of business • Britannia has cultivated key relationships with large, resilient clients who see
Slide 12: Large & Rapidly Growing TAM
numbers LARGE & RAPIDLY GROWING TAM Regulators continue to increase product testing and compliance requirements – while underlying CPG markets grow – compounding the growth for Britannia’s Total Addressable Market (TAM) Market Value – Industry Selection Britannia’s Total Addressable Market $225 16%
Slide 13: Natural Resource Labs
NATURAL RESOURCE LABS Mining Assays, Geochem
Slide 14: Acquisition Growth
ACQUISITION GROWTH • Britannia Mining subsidiary acquired 100% of Paragon Geochemical, based in Sparks, Nevada • Historically profitable business (C$2.5MM 2022 EBITDA) with a full-service offering of fire assay and wet chemistry analysis, supporting the aggressive roll out of Britannia’s PhotonAssay
Slide 15: New Tech in Assay Labs
NEW TECH IN ASSAY LABS Addressing Global Delays In Assays Mining Tech • BMS was established to add capacity to global assay infrastructure through innovative PhotonAssay machines, an industry leading 2 PhotonAssay Units Q4/2023 technology • Assay delays are costly to mining and exploration companies
Slide 16: Chrysos Unit Map
CHRYSOS UNIT MAP Limited competition for PhotonAssay with only 18 units per annum being produced by Chrysos. Estimates of 60 worldwide by end of year 2025. Source: Chrysos 2023H1 Corporate Presentation
Slide 17: Labtech
Labtech AI, big data, advanced insights informed
Slide 18: BLABtech Roadmap
BLABtech Roadmap Technologically enabled testing solutions have been the cornerstone of Britannia’s acquisition strategy. AI is the next iteration in that journey. Providing faster results to clients, with greater transparency, through an inimitable platform which Britannia is introducing to global
Slide 19: BLABtech Development
BLABtech Development o The future of Britannia Life Sciences will expand on and introduce new AI-powered laboratories o AI provides more robust data insights to help researchers make more informed decisions o Algorithms can analyze large datasets and interpret trends without human error o Acquisitio
Slide 20: Contact
CONTACT Peter Shippen peter@britannia.life Canada: +1-416-930-7711 UK: +44(0)7387447441
Britannia Life Sciences — Investor Presentation (January 2024) on 6ix